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Abstract
The a7 nicotinic acetylcholine receptor (nAChR) is a potential target for the treatment of cognitive deficits in patients with
schizophrenia, ADHD and Alzheimer’s disease. Here we test the hypothesis that upregulation of a7 nAChR levels underlies
the enhanced and sustained procognitive effect of repeated administration of a7 nAChR agonists. We further compare the
effect of agonists to that of a7 nAChR positive allosteric modulators (PAMs), which do not induce upregulation of the a7
nAChR. Using the social discrimination test as a measure of short-term memory, we show that the a7 nAChR agonist A-
582941 improves short-term memory immediately after repeated (76daily), but not a single administration. The a7 nAChR
PAMs PNU-120596 and AVL-3288 do not affect short-term memory immediately after a single or repeated administration.
This demonstrates a fundamental difference in the behavioral effects of agonists and PAMs that may be relevant for clinical
development. Importantly, A-582941 and AVL-3288 increase short-term memory 24 hrs after repeated, but not a single,
administration, suggesting that repeated administration of both agonists and PAMs may produce sustained effects on
cognitive performance. Subsequent [
125I]-bungarotoxin autoradiography revealed no direct correlation between a7 nAChR
levels in frontal cortical or hippocampal brain regions and short-term memory with either compound. Additionally, repeated
treatment with A-582941 did not affect mRNA expression of RIC-3 or the lynx-like gene products lynx1, lynx2, PSCA, or Ly6H,
which are known to affect nAChR function. In conclusion, both a7 nAChR agonists and PAMs exhibit sustained pro-cognitive
effects after repeated administration, and altered levels of the a7 nAChR per se, or that of endogenous regulators of nAChR
function, are likely not the major cause of this effect.
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Introduction
Agonists and positive allosteric modulators (PAMs) of the a7
nicotinic acetylcholine receptor (nAChR) are currently being
developed to ameliorate cognitive deficits in diseases such as
schizophrenia, ADHD and Alzheimer’s disease [1,2].
The a7 nAChR desensitizes rapidly in response to high agonist
concentrations in vitro [3,4], which initially led to concern regarding
its applicability as a clinical drug target [5,6]. However, there does
not seem to be development of tolerance regarding the procognitive
effects of a7 nAChR agonists in animal models (reviewed in [7]).
Thus, repeated a7 nAChR agonist administration has been shown
to improve auditory gating, Morris water maze learning, classical
eyeblink conditioning, inhibitory avoidance and novel object
recognition [8–13]. Importantly, repeated, but not acute, admin-
istration of the a7 nAChR agonist TC-5619 improves performance
in the novel object recognition test [14], indicating an enhanced
effect with repeated administration in this test. Furthermore, it has
been shown that agonists of nAChRs can produce long-lasting
cognitive effects that outlast the presence of the compounds in the
body [15,16]. Furthermore, [
3H]-nicotine binding sites correlate
with performance in the Morris water maze task several days after
nicotine administration [17], suggesting that the prolonged effects
were mediated by an increased number of nAChRs. Specifically for
the a7 nAChR, it has been shown that the a7 nAChR agonist,
AZD0328 enhances novel object recognition and increases [
125I]-
bungarotoxin (BTX) binding in mice 4–48 hours after administra-
tion [18]. In a related study AZD0328 enhanced performance in a
delayedresponsetaskinmonkeyswitheffectsevident morethanone
month after administration of the compound [19]. Taken together,
these studies suggest that increased receptor numbers may underlie
the sustained cognitive effects of nAChR agonists, although a direct
correlation between a7 nAChR levels and cognitive performance
has not been investigated.
PAMs of the a7 nAChR increase the response to an agonist and
are divided into two types depending on whether they also decrease
desensitization of the receptor (type II) or not (type I) [20].
Compared to agonists, there is much less data regarding the
cognitive effects of a7 nAChR PAMs in animals, and no published
clinical data. However, documented effects include improvements
of pre-pulse inhibition and auditory gating as well as short- and
long-term memory [21–25], resembling the behavioral effects of the
agonists. Since PAMs do not activate the receptor per se, but
modulate the effects of endogenous transmitters, they may enable
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agonists [2], buton the other hand,a lackof activation by the PAMs
alone may hamper their effectiveness in patients with decreased
levels of endogenous activation. It is thus not clear whether agonists
or PAMs are preferable for clinical use, or whether there are
qualitative differences between these types of compounds in vivo in
terms of repeated administration.
We have recently demonstrated a fundamental in vivo difference
between agonists and PAMs in that acute or repeated adminis-
tration of the former, but not the latter, increases [
125I]-BTX
binding sites in the rat brain, reflecting an increased number of a7
nAChRs [26]. Given that upregulation of the a7 nAChR might
underlie the enhanced procognitive effect seen with repeated
administration of a7 nAChR agonists, as well as the long-lasting
cognitive effects of these compounds, it is pertinent to examine
whether a7 nAChR PAMs exhibit similar properties, since they do
not induce upregulation of the receptor.
Here we use a rat social discrimination test to examine whether
the a7 nAChR agonist A-582941 or the a7 nAChR PAMs, AVL-
3288 (type I) or PNU-120596 (type II), has procognitive effects after
acute or repeated administration, respectively, and whether such
effects arelong-lasting.In addition,we relate the behavioral effect of
the compounds to their effect on a7 nAChR binding sites in the
brain as well as activation of intracellular signalling cascades.
Results
A-582941 and AVL-3288 enhance performance in the
social discrimination test
Rats were injected subcutaneously (s.c.) with 10 mg/kg A-
582941, 1 mg/kg AVL-3288, 3 mg/kg PNU-120596, or vehicle
once daily for seven days. They were tested in the social
discrimination test 4 times: on the day of the first injection;
24 hours after the first injection, but before the second injection;
on the day of the seventh injection; and 24 hours after the last
injection (Fig. 1A).
A single injection of either A-582941, AVL-3288, or PNU-
120596 did not affect the preference of rats for a novel versus
familiar juvenile, neither immediately (after a 2 hour intertrial
interval) nor 24 hours after administration (Fig. 1B and C).
However, when tested immediately after the last of seven daily
injections, A-582941-treated rats exhibited a significantly en-
hanced preference index compared to vehicle-treated rats (Fig. 1D,
P,0.05), whereas AVL-3288 and PNU-120596 had no effect.
When tested 24 hours after the last administration, A-582941-
treated rats still exhibited a significantly enhanced preference
index (Fig. 1E, P,0.01). At this time point, AVL-3288-treated
animals also has a significantly increased preference index
(P,0.05), whereas there was no effect of PNU-120596.
The exploration time during the first trial of each test was
analyzed, and there was no significant difference between groups
in terms of exploration of the familiar stimulus rat (data not
shown). Also, the total exploration time, i.e. the time spent
exploring the familiar and novel stimulus rat, during the second
trial did not significantly differ between groups in any of the tests.
No correlation between performance in the social
discrimination test and brain [
125I]-bungarotoxin binding
After the final social discrimination test, rats were decapitated,
and [
125I]-BTX autoradiography was performed on coronal brain
sections from the frontal cortex and hippocampus.
A-582941-treated animalshadsignificantlyincreased[
125I]-BTX
binding in the outer and inner layers of the medial prefrontal cortex
Figure 1. Effect of acute and repeated administration of a7 nAChR ligands in the social discrimination test. Rats were injected with A-
582941 (A-58, 10 mg/kg), AVL-3288 (AVL, 1 mg/kg), PNU-120596 (PNU, 3 mg/kg), or vehicle (Veh, 5% DMSO, 8% Solutol in saline) once daily for seven
days. (A) Diagram of the schedule for injections and behavioral testing. The rats were tested in the social discrimination test (B) on the day of the first
injection (n=13–20), (C) 24 hours after the first injection, but before the second injection (n=10–14), (D) on the day of the seventh injection (n=9–
18), and (E) 24 hours after the last injection (n=10–24). Neither compound affected social discrimination after a single injection. However, daily
injection of A-58 for 7 days significantly increased the preference for exploring the novel juvenile compared to the familiar one, indicating an increase
in short-term memory. Importantly, this effect was still detectable 24 hours after the last injection. At this time point, AVL also produced a significant
increase in the preferatory index. * P,0.05 and ** P,0.01 indicate significant difference from vehicle in a one-way ANOVA with Dunnett’s multiple
comparison test. Error bars indicate the standard error of the mean.
doi:10.1371/journal.pone.0027014.g001
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CA2/3 region of the hippocampus compared with vehicle-treated
rats, whereas they did not differ from controls in the CA1 or dentate
gyrus (DG) regions of the hippocampus (Fig. 2). PNU-120596
significantly increased [
125I]-BTX binding in the CA1, whereas
AVL-3288 did not affect binding in any region measured.
In an attempt to see whether there was a connection between a7
nAChR levels and cognitive performance, we correlated the
performance of rats in the social discrimination test 24 hours after
the last of seven drug administrations with brain [
125I]-BTX
binding. Neither A-582941-, PNU-120596-, AVL-3288- nor
vehicle-treated rats displayed any significant correlations between
performance in the social discrimination index and [
125I]-BTX
binding in any region measured (Fig. 3).
PNU-120596 and AVL-3288 do not affect A-582941-induced
immediate-early gene expression in the frontal cortex
Juvenile rats were injected s.c. with 3 mg/kg PNU-120596,
1 mg/kg AVL-3288, or vehicle once daily for 7 days (pretreat-
ment). 4 hours after the last injection, the animals received an
acute challenge of 10 mg/kg A-582941 or vehicle and were
decapitated 1 hour later (Fig. 4A). Radioactive in situ hybridi-
zation was performed for the immediate-early genes (IEGs)
activity-regulated cytoskeleton-associated protein (arc) and c-Fos,
on coronal brain sections from the frontal cortex.
A two-way ANOVA on Arc mRNA expression with pre-
treatment and acute treatment as the fixed factors showed a
significant main effect of acute administration of A-582941 in the
mPFCandVLO(P,0.0001),butnomaineffectofthepre-treatment
(P=0.87andP=0.21, respectively) and no interaction between the
effects of pre-treatment and acute treatment (P=0.18andP=0.43,
respectively, Fig. 4B). Subsequent Bonferroni-corrected t-tests
showed that acute administration of A-582941 significantly increased
Arc mRNA in the mPFC in vehicle-, PNU-120596-, and AVL-3288-
pretreatedrats,whereasthe compound onlyincreased ArcmRNAin
the VLO in vehicle- and PNU-120596-pretreated rats.
A similar picture emerged for c-Fos mRNA, although the
degree of induction with A-582941 was smaller overall (Fig. 4C).
Thus, a two-way ANOVA on c-Fos mRNA expression showed a
significant main effect of acute administration of A-582941 in the
mPFC and VLO (P,0.0001 and P=0.0006, respectively), but no
main effect of the pre-treatment (P=0.40 and P=0.08, respec-
tively) and no interaction (P=0.13 and P=0.12, respectively).
Subsequent Bonferroni-corrected t-tests showed that acute admin-
istration of A-582941 significantly increased c-Fos mRNA in the
mPFC in PNU120596- and AVL-3288-pretreated rats,
and increased c-Fos mRNA in the VLO in PNU-120596-pretreated
rats.
Repeated A-582941 administration does not affect mRNA
levels of endogenous regulators of a7 nAChR expression
and function in the frontal cortex or hippocampus
Juvenile rats were administered 10 mg/kg A-582941 or vehicle
s.c. once daily for 7 days and were decapitated 1, 4, 10, 24, 72 or
Figure 2. Brain [
125I]-bungarotoxin binding in rats tested in the social discrimination test. Rats that underwent the injection and testing
scheme described in Fig. 1 were decapitated immediately after the last social discrimination test. [
125I]-bungarotoxin (BTX) binding was analyzed
using optical density (OD) in the outer (I–IV) and inner (V–VI) layers of the medial prefrontal cortex (mPFC), the ventrolateral orbitofrontal cortex (VLO)
as well as the CA1, CA2/3 and dentate gyrus (DG) regions of the hippocampus. A-582941 (A-58, n=27)-treated rats had significantly increased [
125I]-
BTX binding in the outer and inner layers of the mPFC, the VLO and the CA2/3, compared with vehicle-treated rats (Veh, n=26). PNU-120596 (PNU,
n=20) increased [
125I]-BTX binding in the CA1, and AVL-3288 (AVL, n=8) did not affect [
125I]-BTX binding in any region measured. * P,0.05,
** P,0.01, and *** P,0.001 indicate significant difference from vehicle-treated rats in a one-way ANOVA with Dunnett’s multiple comparison test
performed separately for each region. Error bars indicate the standard error of the mean.
doi:10.1371/journal.pone.0027014.g002
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were decapitated after 1 hour (n=6) or 7 days (n=5), and since
there was no difference in gene expression between the two groups
(Student’s t-test, data not shown), they were pooled. Tissue from
the frontal cortex and hippocampus was dissected and analyzed
using real-time qPCR.
A-582941 significantly increased RIC-3 mRNA expression in
the frontal cortex 3 days after the last administration (Fig. 5).
A-582941 did not significantly affect lynx1, lynx2, prostate
stem cell antigen (PSCA), or Ly6H expression in the frontal
cortex or hippocampus at any time point. However, there was a
trend towards an increase in PSCA expression in the hippocampus
Figure 3. Correlation between performance in the social discrimination test and brain [
125I]-bungarotoxin binding. The performance
of rats in the social discrimination test 24 hours after the last of seven drug administrations, as described in Figure 1, was correlated with brain [
125I]-
bungarotoxin (BTX) binding, as described in Figure 2. Neither A-582941 (A-58, n=19), PNU-120596 (PNU, n=14), AVL-3288 (AVL, n=8) or vehicle (Veh)
treated rats displayed any significant correlations between performance in the social discrimination index and [
125I]-BTX binding in any region measured.
Correlation was determined as a slope that was significantly different from zero in a linear regression performed separately for each group in each region.
doi:10.1371/journal.pone.0027014.g003
Figure 4. Repeated administration of PNU-120596 or AVL-3288 does not affect A-582941-induced Arc and c-Fos mRNA expression
in the frontal cortex. Juvenile rats were administered PNU-120596 (PNU, 3 mg/kg), AVL-3288 (AVL, 1 mg/kg), or vehicle (5% DMSO, 8% Solutol in
saline) once daily for 7 days. 4 hours after the last injection, the animals received an acute challenge of A-582941 (A-58, 10 mg/kg) or saline, and were
decapitated 1 hour later. (A) A diagram of the experimental setup. Arc (B) and c-Fos (C) mRNA expression was analyzed using radioactive in situ
hybridization in the medial prefrontal cortex (mPFC, layer II–VI) and the ventrolateral orbitofrontal cortex (VLO). A two-way ANOVA on Arc or c-Fos
mRNA expression with repeated and acute treatment as the fixed factors showed a significant main effect of A-58-administration, but no interaction.
Subsequent Bonferroni-corrected t-tests showed that the challenge with A-58 increased Arc mRNA in all groups except in the AVL-pretreated group
in the VLO. Concerning c-Fos, there was only a significant effect of A-58 only in the PNU- and AVL-pretreated groups in the mPFC and only in the
PNU-pretreated group in the VLO. N=6. * P,0.05 and ** P,0.01 indicate significant difference from respective vehicle controls in a Bonferroni-
corrected t-test performed separately for each region. Error bars indicate the standard error of the mean.
doi:10.1371/journal.pone.0027014.g004
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hippocampus.
Discussion
The main findings in this study are that the memory-enhancing
effect of the a7 nAChR agonist A-582941 in the social
discrimination test is increased with repeated administration, and
that repeated administration produces a sustained memory-
enhancement. Furthermore, we demonstrate that the type I
PAM, AVL-3288, also exhibits sustained memory-enhancing
effects, whereas the type II PAM, PNU-120596, does not.
Repeated administration of A-582941 significantly enhanced
short-term memory performance in the social discrimination test,
whereas we did not observe an effect of a single administration of
the compound. This finding is in accordance with a study showing
that repeated, but not acute, administration of the a7 nAChR
agonist TC-5619 improves performance in the novel object
recognition test [14]. Similarly, 14 daily doses, but not one acute
dose, of the a7 nAChR agonist SSR180711 mitigates a PCP-
induced impairment in the novel object recognition test [27].
These results illustrate that analysis of the acute effects of a7
nAChR agonists does not reveal their full range of effect, and that
the enhancement of effect is not restricted to the social domain.
It should be noted that acute effects of A-582941 have been
demonstrated in a social recognition test, similar to the test used
here [11]. This difference may arise because we use higher doses
than in the previous study used, or because our version of the test
might be less sensitive to the effects of a7 nAChR agonists.
Neither single nor repeated administration of the a7 nAChR
PAMs PNU-120596 nor AVL-3288 produced immediate effects
on social discrimination. This demonstrates a fundamental
difference between PAMs and agonists of the a7 nAChR in
relation to the cognitive effects of repeated administration.
We further demonstrated that the pro-cognitive effect of
repeated administration of A-582941 was sustained 24 hours after
the last administration, whereas there was no effect 24 hours after
a single administration. This suggests that neural changes occur
with repeated administration that are not seen after a single
exposure. Very low doses of the a7 nAChR agonist AZD0328
have been shown to enhance novel object recognition in mice 4–
48 hours after a single administration [18]. Although exposure to
Figure 5. Effect of repeated A-582941 administration on expression of endogenous regulators of a7 nAChR function in the frontal
cortex and hippocampus. Juvenile rats were administered A-582941 (10 mg/kg) or vehicle once daily for 7 days and were decapitated at the
stated time after the last administration. Tissue from the frontal cortex (FC) and hippocampus (HIP) was dissected and analyzed using real-time qPCR.
Vehicle-treated animals were decapitated after 1 hour (n=6) or 7 days (n=5), and since there was no difference between the two groups (Student’s
t-test), they were pooled. A-582941 significantly increased RIC-3 mRNA expression in the frontal cortex 3 days after the last administration. A-582941
did not significantly affect lynx1, lynx2, PSCA, or Ly6H expression in the frontal cortex or hippocampus at any time point. N=6 (11 for vehicle).
* P,0.05, ** P,0.01, and *** P,0.001 indicate significant difference from vehicle controls in a one-way ANOVA with Dunnett’s multiple comparison
test performed separately for each region. Error bars indicate the standard error of the mean.
doi:10.1371/journal.pone.0027014.g005
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confer particular effects [18,19], this may indicate that our results
are not due to a qualitative difference between the effects of a
single and repeated administration, in terms of a prolonged effect,
but rather an enhancement of a weak initial effect that is not
picked up in the social discrimination test.
Despite the lack of an immediate effect, AVL-3288 enhanced
short-term memory in the social discrimination test 24 hours after
the last of seven injections. Contrarily, the type II PAM PNU-
120596 had no long-term effect on social discrimination. This
points towards a potential behavioral difference between type I
and II a7 nAChR PAMs. Future studies are required to determine
whether such long-term effects are unique to AVL-3288 or a
general feature of type I a7 nAChR PAMs.
Several possible mechanisms may underlie the increased and
sustained cognitive effects seen with repeated administration of A-
582941 and AVL-3288, including a lowering of the threshold for
LTP induction, increased nerve growth factor expression, IEG
induction, and nAChR upregulation [15]. In line with this, we
have previously demonstrated an increased amount of a7 nAChRs
as well as an increased IEG response to a subsequent challenge
with an a7 nAChR agonist after repeated administration with A-
582941 in juvenile rats [26]. Contrarily, we show here that the
IEG response to a challenge with an a7 nAChR agonist was not
significantly altered in AVL-3288- or PNU-120596-pretreated
animals. This lends credence to the idea that the immediate
enhancement of the pro-cognitive effect of A-582941 with
repeated treatment may be due to an enhanced responsiveness
to a7 nAChR agonists at the cellular level, as reflected in an
increased IEG response. This, however, does not explain the
sustained effects on cognition seen with A-582941 and AVL-3288.
The enhanced cellular responsiveness could be caused by an
increase in a7 nAChR levels. An alternative explanation for the
enhanced effect is that A-582941 may initially desensitize a7
nAChRs, thus obscuring an acute effect. This effect may be
lessened with repeated administration, leading to the observed
enhancement of short-term memory.
We further show that repeated administration of A-582941
increases BTX binding, as a measure of a7 nAChR levels, in adult
rats. Contrarily, neither AVL-3288 nor PNU-120596 produced
widespread increases in BTX binding, although PNU-120596 did
significantly increase BTX binding in the CA1 region of the
hippocampus. Importantly, there was no direct correlation
between short-term memory 24 hours after the last of seven daily
doses and BTX binding in the frontal cortex or hippocampus for
any group of animals. Therefore, the sustained cognitive enhance-
ment observed with A-582941 and AVL-3288, and previously
demonstrated with other a7 nAChR agonists [16,18,19], is not
likely due to an increase in receptor levels per se. There is also no
correlation between short-term memory and BTX levels in
vehicle-treated rats, suggesting that a7 nAChR levels are not the
major determinant of performance in the social discrimination
test.
It has been shown that a7 nAChR knockout mice display
reduced attentional performance particularly with increased
attentional load [28,29], suggesting that the a7 nAChR is more
important in situations of high attentional demand. It is therefore
possible that a more demanding task might reveal a direct
correlation between a7 nAChR levels and cognitive performance.
Notably, [
125I]-BTX autoradiography measures a7 nAChRs
located both internally and at the cell surface. Therefore, we
cannot exclude a possible correlation between surface receptors
and performance. In addition, binding experiments, such as with
BTX, favour conversion of receptors to a desensitized state, which
has a higher affinity for ligand binding [30]. Therefore, BTX
binding does not necessarily give an accurate measure of the pool
of responsive receptors.
The lack of a widespread effect of AVL-3288 and PNU-120596
on BTX binding corresponds with our previous data showing a
lack of effect of the PAMs PNU-120596 and NS1738 on BTX
binding in non-performing juvenile rats [26], and suggests that the
lack of effect of the PAMs is not due to a low cholinergic tone in
non-performing animals, since the cholinergic tone would be
expected to be much higher in animals that have undergone the
social discrimination test [31].
A number of proteins have been described, which regulate the
expression or function of nAChRs. These include RIC-3, which
increases expression of a7 nAChRs [32,33], and the lynx-like
proteins lynx1, lynx2, PSCA, and Ly6H, which regulate the ion
channel function of nAChRs, possibly by acting as allosteric
modulators [34,35]. We did not find a significant change in lynx1,
lynx2, PSCA, or Ly6H mRNA expression in the frontal cortex or
hippocampus of juvenile rats repeatedly administered A-582941,
although there was a trend towards increased Ly6H expression in
both the frontal cortex and hippocampus that matched the time-
course of a7 nAChR upregulation, which has previously been
assessed in the same animals [26]. However, Ly6H has been
demonstrated not to bind to the a7 nAChR [36]. We did find a
significant upregulation of RIC-3 mRNA in the frontal cortex 3
days after the final administration. However, the time course for
upregulation of RIC-3 does not match that of a7 nAChR BTX
binding sites, which peak after 4 hours [26]. It is therefore not
likely that upregulation of RIC-3 is responsible for agonist-induced
upregulation of the a7 nAChR
Taken together, these results suggest that the immediate
procognitive effects of an a7 nAChR agonist are enhanced with
repeated administration, possibly due to increased responsiveness
at the cellular level, as reflected in an increased immediate-early
gene response [26]. Furthermore, we demonstrate that both a7
nAChR agonists and type I PAMs may produce long-term
improvement of cognition, and that this does not correlate with
changes in a7 nAChR levels per se or that of known regulators of
nAChR function.
Materials and Methods
Animals
A total of 154 Adult (172–300 g at the end of experiments), 84
juvenile (36 days, 100–140 g at the end of experiments) and 32
young juvenile (25–28 days, 52–88 g) male Wistar rats were
purchased from Taconic Europe (Ll. Skensved, Denmark). The
animals were acclimatized under standardized conditions with free
access to food and water for a minimum of 5 days after arrival.
Young juvenile rats were housed separately to avoid transfer of
odors between animals. All experiments were conducted in
accordance with the Declaration of Helsinki, the Danish National
Guide for Care and Use of Laboratory animals and the European
Communities Council Directive of 24 November 1986 (86/609/
EEC).
Drug treatment and tissue collection
A-582941 [11] and PNU-120596 [21] were synthesized at the
Department of Medicinal Chemistry at NeuroSearch A/S. AVL-
3288 (also known as XY4083 and CCMI) [22] was a kind gift from
Kelvin W. Gee, University of California, Irvine. The compounds
were injected s.c. at 2 ml/kg.
Four batches of adult rats (to a total of 154 rats) were tested in
the social discrimination task. The rats were injected with vehicle
Alpha7 nAChR Ligands and Memory Enhancement
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3 mg/kg PNU-120596 once daily for 7 days and tested on day 1,
2, 7, and 8. All animals that completed the fourth test (81 rats)
were decapitated immediately after the test and their brains
assayed for [
125I]-BTX binding.
36 juvenile rats were injected with vehicle (5% DMSO, 8%
Solutol in 0.9% saline), 1 mg/kg AVL-3288, or 3 mg/kg PNU-
120596 once daily for 7 days, and 4 hours after the last injection,
they received an injection of vehicle or 10 mg/kg A-582941 and
were decapitated 1 hour later.
48 juvenile rats were injected with vehicle (0.9% NaCl) or
10 mg/kg A-582941 once daily for 7 days and decapitated 1, 4,
10, 24 hours, 3, or 7 days after the last injection.
For all experiments, the brains were dissected and divided into
two hemispheres. One hemisphere was frozen directly in
powdered dry ice, whereas the prefrontal cortex and hippocampus
were dissected from the other hemisphere before freezing.
Social discrimination
The social discrimination test was modified from [37]. Briefly,
an adult male Wistar rat was put into a clean standard rat cage
(43627618 cm) with a small amount of bedding $60 min before
the test. Immediately before testing, the cage was gently moved to
a testing platform fitted with a video camera, the lid was removed,
and a young juvenile (25–28 days) male rat was introduced into the
cage. A transparent plastic plate was quickly placed on top of the
cage, and the rats were recorded for 5 min (trial 1). After trial 1,
the juvenile rat was removed, the lid replaced, and the cage moved
back to its original place. Drug injections, were given immediately
after trial 1. After an inter-trial interval of 120 min, a second trial
was performed. Trial 2 was identical to trial 1, except that two
juvenile rats were introduced – the same juvenile as in trial 1
(familiar), and a juvenile that the adult rat had never seen before
(novel). The amount of time the adult rat spent exploring the
juveniles in trial 1 and 2 was measured by an observer blind to the
treatment of the rats. Social exploration was defined as including
sniffing, licking, and chewing fur of the juvenile, as well as pawing
and close following of the juvenile. Exploration initiated by the
juveniles was not included. The exploration in trial 2 is presented
as a preference index, which is the difference between the time
spent interacting with the novel and familiar juvenile divided by
the total interaction time. The young adult rats were used for
multiple tests, but were never used for more than one test with the
same adult rat.
Autoradiography
Brain hemispheres were cut into 12 mm serial coronal sections
on a cryostat and directly thaw-mounted onto super frost glass
slides. Sections were collected in parallel series with 4–6 sections
per glass slide throughout the prefrontal cortex (6 series, 2.8–
3.2 mm anterior to Bregma) and the dorsal hippocampal region (6
series, 3.6–4.0 mm posterior to Bregma) (Paxinos and Watson
1986). Two slides from each animal were thawed at room
temperature for 30 min, followed by 30 min hydration in 50 mM
Tris buffer, pH 7.3 (binding buffer). Slides were then incubated
2 hours in binding buffer containing 0.5 nM [
125I]Tyr-54-mono-
iodo-a-bungarotoxin (2,200 Ci/mmol, Perkin Elmer, Skovlunde,
Denmark) to asses total binding. For analysis of non-specific
binding, 1 mM (2)-nicotine (Sigma-Aldrich, Brøndby, Denmark)
was included in the incubation. Slides were then briefly washed in
binding buffer, followed by 2630 min washes in ice-cold binding
buffer and rinsed briefly in ice-cold distilled water. Slides were
then dried under an air stream and fixated overnight at 4uCi na
sealed chamber containing paraformaldehyde vapor. Finally,
slides were dried 2–3 hours in an excicator, exposed to a BAS-
MS2040 phosphor imaging plate (Science Imaging Scandinavia
AB, Nacka, Sweden) for ,4 hours and scanned with a BAS-2500
imaging plate scanner (Fujifilm Europe GmbH, Du ¨sseldorf,
Germany).
Quantitative assessment of mRNA levels
Total RNA was isolated with Trizol Reagent (Sigma-Aldrich,
Brøndby, Denmark) according to the manufacturer’s directions.
The samples were dissolved in RNase-free water and RNA content
was quantified using a Nanodrop ND-1000 spectrophotometer
(Nanodrop Technologies, Wilmington, DE). Extracted RNA was
reverse transcribed into single-stranded cDNA with the ImProm-
II
TM reverse transcription kit (Promega, Madison, WI) according
to the manufacturer’s directions using oligo(dT)15 primers, 6 mM
MgCl2, and 20 units of RNase inhibitor.
Real-time qPCR reactions were performed in a total volume of
20 ml, containing 1 ml sample cDNA, 16Brilliant II SYBR green
mastermix (Stratagene, La Jolla, CA), and 15 pmol each of the
forward and reverse primer (DNA technology, Aarhus, Denmark).
PCR was performed on a Light Cycler 480 (Roche, Indianapolis,
IN) with a 10 minute preincubation at 94uC followed by 40 cycles
of 30 seconds at 94uC, 45 seconds at 60uC and 1.5 minutes at
72uC. All primers were validated by using serially diluted cDNA to
establish a standard curve, and by confirming the size of the
product on a DNA gel (data not shown). The primers used are
described in Table 1. Quantification of mRNA expression was
performed according to the comparative CT method as described
in [38]. For each sample, the amount of target mRNA was
normalized to that of the reference gene GAPDH.
In situ hybridization
In situ hybridization was performed as previously described [26].
Two different synthetic oligonucleotide DNA probes (DNA
Table 1. Primers used for real-time qPCR.
Gene Forward primer 59-39 Reverse primer 59-39 Product size
RIC-3 CAGCACTGATAACACACATGTGG GCAGGCTGCTTTCACTCAAAA 75 bp
Lynx1 ACCACTCGAACTTACTTCACC ATCGTACACGGTCTCAAAGC 81 bp
Lynx2 GTTCTGGCTTCCAGGGCTGG GGCTGCTGACGATGCACACG 191 bp
PSCA GCCCTACCAGTTCTGATCAG TCACACCCACCTAGCTTCAT 154 bp
Ly6H CTACTGGCCTTGCTTCTCTG AATGATCCTTCCTGCTGCTG 163 bp
GAPDH CATCAAGAAGGTGGTGAAGCA CTGTTGAAGTCACAGGAGACA 93 bp
doi:10.1371/journal.pone.0027014.t001
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of rat Arc cDNA [39] and bases 132–179 of rat c-Fos cDNA [40],
respectively, were used.
Quantification and data analysis
Mean optical densities from autoradiography and in situ
hybridization were quantified in the regions of interest using a
computer image analysis system (Quantity OneH, Bio-Rad, CA) by
an observer blinded to the treatment of the animals. The
individual value for each region was calculated as the average
measurement from three individual sections. For autoradiography,
the average value from an adjacent slice with non-specific binding
was subtracted to yield specific binding. For in situ hybridization,
background values were measured for each slide individually in a
tissue-free area and subtracted from each measurement on that
slide. The presented values are the measured value minus the
background/non-specific measurement, normalized to the level of
the respective vehicle group.
Data were analyzed using two-way ANOVA, one-way ANOVA
followed by Dunnett’s Multiple Comparison test, or Bonferroni-
corrected t-tests as appropriate. Linear regression was used to
correlate [
125I]-BTX binding with performance in the social
discrimination test. The statistical calculations were performed
using GraphPad Prism version 5.03 for Windows (GraphPad
Software, San Diego, USA). All data are presented as mean6
standard error of the mean, and a P-value of less than 0.05 was
considered statistically significant.
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